Literature DB >> 11319917

Transgene expression in mouse airway epithelium by aerosol gene therapy with PEI-DNA complexes.

A Gautam1, C L Densmore, E Golunski, B Xu, J C Waldrep.   

Abstract

Gene therapy targeted at the respiratory epithelium holds therapeutic potential for diseases such as cystic fibrosis and alpha-1 anti-trypsin deficiency. A variety of approaches such as intranasal or intratracheal instillation and aerosol delivery have been utilized to target genes to the airways. Polyethylenimine (PEI), a linear or branched polycationic polymer, has been used for delivery of genes to various organs. In this study, using fluorescein isothiocyanate (FITC)-labeled branched PEI, we initially examined the localization of PEI in the lungs after aerosol delivery to Balb/C mice. Further, after aerosol delivery of PEI-CAT DNA, in situ immunostaining for chloramphenicol acetyl transferase (CAT) protein was used to localize the transgene expression within the lungs. Immunohistochemistry for CAT, as well as localization of FITC-labeled PEI, revealed that after aerosol delivery, the PEI-DNA complexes deposit and subsequently transfect most of the epithelial cells in the conducting airways (including the peripheral airways). High levels of CAT were detected at 24 h after aerosol exposure and significant CAT expression was detected in the lungs up to 28 days after a single aerosol exposure. The data suggest that aerosol delivery of PEI-DNA complexes could be effective for the treatment of pulmonary diseases such as cystic fibrosis and alpha-1 anti-trypsin deficiency.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11319917     DOI: 10.1006/mthe.2001.0300

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  31 in total

Review 1.  Aerosol gene therapy.

Authors:  Ajay Gautam; J Clifford Waldrep; Charles L Densmore
Journal:  Mol Biotechnol       Date:  2003-01       Impact factor: 2.695

2.  Efficient active transport of gene nanocarriers to the cell nucleus.

Authors:  Junghae Suh; Denis Wirtz; Justin Hanes
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

3.  Efficient generation of mucosal and systemic antigen-specific CD8+ T-cell responses following pulmonary DNA immunization.

Authors:  Maytal Bivas-Benita; Liat Bar; Geoffrey O Gillard; David R Kaufman; Nathaniel L Simmons; Avi-Hai Hovav; Norman L Letvin
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

4.  Design and characterization of microporous hyaluronic acid hydrogels for in vitro gene transfer to mMSCs.

Authors:  Talar Tokatlian; Cynthia Cam; Shayne N Siegman; Yuguo Lei; Tatiana Segura
Journal:  Acta Biomater       Date:  2012-07-20       Impact factor: 8.947

Review 5.  Gene therapy of cystic fibrosis (CF) airways: a review emphasizing targeting with lactose.

Authors:  D T Klink; M C Glick; T F Scanlin
Journal:  Glycoconj J       Date:  2001-09       Impact factor: 2.916

Review 6.  Gene therapy of cystic fibrosis: the glycofection approach.

Authors:  I Fajac; P Briand; M Monsigny
Journal:  Glycoconj J       Date:  2001-09       Impact factor: 2.916

7.  Non-viral DNA delivery from porous hyaluronic acid hydrogels in mice.

Authors:  Talar Tokatlian; Cynthia Cam; Tatiana Segura
Journal:  Biomaterials       Date:  2014-01       Impact factor: 12.479

Review 8.  Barriers to inhaled gene therapy of obstructive lung diseases: A review.

Authors:  Namho Kim; Gregg A Duncan; Justin Hanes; Jung Soo Suk
Journal:  J Control Release       Date:  2016-05-16       Impact factor: 9.776

9.  Repeated aerosol delivery of carboxyl-terminal modulator protein suppresses tumor in the lungs of K-rasLA1 mice.

Authors:  Soon-Kyung Hwang; Hwang-Tae Lim; Arash Minai-Tehrani; Eun-Sun Lee; Jongmin Park; Seung Bum Park; George R Beck; Myung-Haing Cho
Journal:  Am J Respir Crit Care Med       Date:  2009-03-12       Impact factor: 21.405

10.  Polyethylenimine-mediated gene delivery to the lung and therapeutic applications.

Authors:  Sante Di Gioia; Massimo Conese
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.